James M. Wilson, MD, PhDFounder

United States - ND

My research career spans over 40 years and has focused on basic, translational, and clinical investigation of rare diseases and ways to treat them via gene therapy and genome editing. I now serve as the President and CEO of GEMMA Biotherapeutics (GEMMABio, a company developing advanced rare disease therapies) and Chairman of Franklin Biolabs (a genetic medicines contract research organization/CRO). In my academic career as a Professor at the Perelman School of Medicine of the University of Pennsylvania, I directed the Gene Therapy Program and Orphan Disease Center. Over the years, I have worked to advance gene therapy technologies that emphasize safety and efficacy, lead national dialogue about the disruptive nature of novel gene therapies on traditional business models, and ultimately advocate for global access to these advanced therapies for all rare disease patients.